CCR6 receptor modulators

A compound of Formula (I)

• wherein
• Q represents N, CH, or C—R, wherein R represents halogen or C1-3-alkyl;
• R1 represents
• C1-3-alkyl;
• R2 represents
• hydrogen;
• C1-4-alkyl;
• hydroxy-C1-3-alkyl;
• C1-3-fluoroalkyl;
• or
• C3-5-cycloalkyl;
• R3a represents
• halogen;
• C1-5-alkyl;
• C1-3-fluoroalkyl;
• C1-3-fluoroalkoxy;
• C3-5-cycloalkyl;
• or
• 1-(C1-3-fluoroalkyl)-C3-5-cycloalkyl;
• R3b represents
• hydrogen;
• or
• halogen;
• R4 represents
• C1-4-alkyl which is unsubstituted;
• mono-substituted, wherein the substituent is selected from hydroxy or C1-3-alkyl-amino;
• or di-substituted, wherein the first substituent represents hydroxy, and the second substituent represents C1-fluoroalkyl;
• or
• -L-Cy, wherein
• -L- represents a direct bond or —CH2—;
• and
• Cy represents C3-7-cycloalkyl optionally containing one ring heteroatom selected from nitrogen or oxygen;
• wherein Cy independently is unsubstituted;
• or
• mono-substituted with
• hydroxy;
• oxo;
• C1-4-alkyl;
• —C(═O)RA, wherein RA represents C1-3-alkyl or hydroxy-C1-3-alkyl;
• or
• C1-3-alkyl-carbonyl-amino;
• or
• di-substituted, wherein the first substituent represents oxo, and the second substituent represents C1-3-alkyl;
• or di-substituted, wherein the first substituent represents hydroxy and the second substituent represents C1-3-alkyl-carbonyl;
• or Cy represents a saturated 5- to 8-membered bridged bicyclic hydrocarbon ring system, wherein Cy independently is mono-substituted, wherein the substituent is selected from
• hydroxy-C1-3-alkyl;
• or
• —C(═O)RB, wherein RB represents
• hydroxy;
• —NRN1RN2, wherein RN1 and RN2 independently represent hydrogen or C1-3-alkyl;
• or RN1 and RN2 together with the nitrogen atom to which they are attached form pyrrolidinyl;
• or
• C1-3-alkoxy;
• or Cy represents a 5- or 6-membered heteroaryl containing one or two ring heteroatoms independently selected from nitrogen or oxygen;
• and
• R5 represents
• C1-4-alkyl;
• hydroxy-C1-3-alkyl;
• C1-3-alkoxy-C1-3-alkyl;
• C3-7-cycloalkyl;
• C1-3-fluoroalkyl;
• C1-3-alkyl-carbonyl;
• or
• C1-3-alkyl-carbonyl-amino-C1-3-alkyl;
• or R4 and R5 together with the triazolyl ring to which they are attached form 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridin-2-yl or 6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl;
• or a pharmaceutically acceptable salt thereof.